Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00894647 · ClinicalTrials.gov registry record · Phase 3
Safety and Effectiveness Study of Actinic Keratosis Treatment Following Cryosurgery
A Phase 3 study, sponsored by Graceway Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 247
- Enrollment target
NCT00894647 is a Phase 3 study that has completed, run by Graceway Pharmaceuticals. The registered enrollment target is 247 participants.
The verdict
NCT00894647, a Phase 3 study, has completed, sponsored by Graceway Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 247 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the efficacy and safety of imiquimod cream versus placebo cream when used after cryosurgery in the treatment of actinic keratoses (AKs).
Interventions
- DRUG placebo cream
- DRUG imiquimod cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 247 participants |
| Start Date | 2009-05 |
| Est. Completion | 2010-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00894647
The ClinicalTrials.gov registry entry for NCT00894647 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 247 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Graceway Pharmaceuticals, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo cream is the first listed.
NCT00894647 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00894647 about?
NCT00894647 is a clinical study titled "Safety and Effectiveness Study of Actinic Keratosis Treatment Following Cryosurgery". The objective of this study is to evaluate the efficacy and safety of imiquimod cream versus placebo cream when used after cryosurgery in the treatment of actinic keratoses (AKs).
What is the current status of trial NCT00894647?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 247 participants. The study started on 2009-05. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00894647?
The interventions under investigation include: placebo cream (DRUG), imiquimod cream (DRUG).
Who is sponsoring clinical trial NCT00894647?
This trial is sponsored by Graceway Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.